Skip to main content

02-07-2019 | Multiple sclerosis | Video

EAN 2019: Alemtuzumab efficacy sustained long-term in relapsing─remitting MS

Giancarlo Comi discusses the outcomes of the TOPAZ study showing sustained efficacy of alemtuzumab on clinical and magnetic resonance imaging outcomes through 8 years in patients with relapsing─remitting multiple sclerosis (1:56).

Funding for independent interviews at EAN 2019 was provided by F.Hoffmann-La Roche Ltd, Basel, Switzerland.

Image Credits